Giant cell arteritis, also called temporal arteritis, is a disease that causes your arteries -- blood vessels that carry oxygen from your heart to the rest of your body -- to become inflamed.

Giant cell arteritis (GCA) is the most common form of vasculitis in the older adult population. There are variable clinical presentations of this entity and no perfect diagnostic test, often ...

Temporal arteritis is also known as cranial arteritis or giant cell arteritis. The condition is a type of vasculitis. According to a review of research published in 2021, the overall incidence of ...

In this Healio Video Perspective, Andrew G. Lee, MD, discusses whether temporal artery ultrasound can be used in place of ...

for the treatment of adults with giant cell arteritis (GCA). 1 This comes after the European Commission recently granted marketing authorization of RINVOQ for the treatment of GCA in adult patients.

Findings showed 46.4% of patients treated with upadacitinib 15mg achieved sustained remission compared with 29.0% of those who received placebo. The Food and Drug Administration (FDA) has approved ...

Temporal arteritis is also known as "giant cell arteritis." Polymyalgia rheumatica generally affects people over age 50. The average age of patients with PMR is 70. The disease is more common ...

AbbVie recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation.

AbbVie (NYSE:ABBV) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), ...

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis (GCA), an autoimmune disease affecting the arteries.

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...